Extended Data Fig. 4: Distribution of biomarkers and PD-L1 IC status. | Nature Medicine

Extended Data Fig. 4: Distribution of biomarkers and PD-L1 IC status.

From: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Extended Data Fig. 4

Analysis of PTEN loss, Teff signature, DNA Damage Response (DDR) alterations and Androgen Receptor (AR) amplification status and PD-L1 IC status. IC0/1 were considered low IC whereas IC2/3 were considered high IC. Numbers on the bars indicate the number of patients being analysed.

Back to article page